Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long‐acting injection: A case report

Kurata, Tsutomu; Hashimoto, Tasuku; Suzuki, Hitoshi

doi:10.1002/npr2.12072

Cited by 3 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Canada, up to 50% of the 1–2% individuals diagnosed with bipolar or schizoaffective disorders, are prescribed long-acting antipsychotics. 12 , 13 This approach is open to controversy, with concerns about the superiority of long-acting compounds in prophylaxis compared with their oral equivalent, the side effect profile of typical and atypical antipsychotics, 14 – 17 and limitations in dopaminergic D2 blockade mechanisms to control mood symptoms. 18 , 19 …”

Section: Introductionmentioning

confidence: 99%

Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry

Stip

Javaid

Bayard-Diotte

et al. 2020

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Background: There is limited data from large naturalistic studies to inform prescribing of long-acting injectable medication (LAIs). Guidance is particularly rare in the case of primary mood disorders. Methods: This study describes prescribing trends of LAIs in 3879 patients in Quebec, Canada, over a period of 4 years. Health register data from the Quebec provincial health plan were reviewed. Results: In this specific registry, 32% of patients who received LAIs drugs for schizophrenia had a confirmed diagnosis of bipolar disorder and 17% had a diagnosis of major depressive disorder. Non-schizophrenia syndromes were preferentially prescribed risperidone long-acting antipsychotic, whereas patients with schizophrenia were prescribed an excess of haloperidol decanoate. Patients with non-schizophrenia disorders prescribed long-acting antipsychotics were more frequently treated in primary care compared with patients with schizophrenia. Conclusion: Data from a large number of patients treated naturalistically in Quebec with long-acting antipsychotics suggests that these compounds, prescribed to treat symptoms of schizophrenia and schizoaffective disorders, were maintained when mood symptoms emerged, even in cases when the diagnosis changed to bipolar disorder. This pragmatic study supports the need to explore this intervention as potential treatment for affective disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry

Stip

Javaid

Bayard-Diotte

et al. 2020

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The possibility of no longer differentiating between established psychosis and the first episode in terms of using LAI has been widely discussed [14,[32][33][34][35][36]. In Early Intervention programs in Quebec, the rate of implantation of LAI would reach up to 50% [8].…”

Section: How Could the Advances Or Research Being Discussed Impact Rementioning

confidence: 99%

“…Studies with other populations than schizophrenia are needed since LAIs are prescribed in mood disorders as well. There is a need to explore better the LAIs' use in affective disorders and may be in other durable or recurrent psychosis with drug use disorder [34][35][36]. Of note, those patients also require antipsychotics and might not be compliant to their drug regimens.…”

Section: How Could the Advances Or Research Being Discussed Impact Rementioning

confidence: 99%

From QAAPAPLE 1 to QAAPAPLE 2: how do we move from one algorithm to another one with Long Acting Antipsychotics (LAIs)

Stip

Grignon

Roy

et al. 2020

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Background: In 2011, the authors published an algorithm summarizing practice guidelines related to the use of long-acting antipsychotics (LAIs) called the Québec Algorithme Antipsychotique à Action Prolongée (QAAPAPLE), and proposed that it be revised every 5-10 years to update it according to most recent scientific knowledge. Therefore, a re-evaluation of the algorithm was conducted to determine which recommendations were still relevant and which needed modification. Methods: The authors conducted a twofold approach: a review of the literature to include new evidence since 2011 (controlled trials, meta-analyses, and practice guidelines); and a participatory component involving electronic surveys, conferences, encounters with opinion leadres, and patients' representatives. Results: Overall, prescribers tended to make decisions based on personal experience and conversations with colleagues rather than consulting evidence-based guidelines. To test if the algorithm was useful worldwide, it was presented in the United Arab Emirates, where the feedback was in agreement with the algorithm and its limitations. Conclusions: Since its initial publication, the QAAPAPLE algorithm has been updated to guide clinicians on the use of LAIs. The new algorithm has also been assessed outside Canada to test its generalizability worldwide, and indicated its flexibility, efficiency, and user-friendliness in order to guide clinicians on the use of LAIs.

show abstract

Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long‐acting injection: A case report

Kurata¹,

Hashimoto

Suzuki³

2019

Neuropsychopharm Rep

Self Cite

View full text Add to dashboard Cite

Alcohol dependence is frequently comorbid with bipolar I disorder. Aripiprazole and its long‐acting injection have demonstrated efficacy in the treatment and prevention of bipolar I disorder and its attendant symptoms, especially manic episodes. However, whether aripiprazole can alleviate alcohol dependence remains controversial. We report the case of a 47‐year‐old woman who had been diagnosed with bipolar I disorder and alcohol dependence, characterized by poor adherence to pharmacological treatment and our hospital's alcoholic treatment program. Consequently, she was repeatedly hospitalized several times per year due to manic episodes and heavy drinking. After treatment with aripiprazole long‐acting injection at a dosage of 400 mg/mo intramuscularly, she has been relapse‐free for over 2 years. Aripiprazole long‐acting injection might therefore be effective for treating patients with bipolar disorder and a comorbid diagnosis of alcohol dependence.

show abstract

Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long‐acting injection: A case report

Cited by 3 publications

References 22 publications

Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry

Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry

From QAAPAPLE 1 to QAAPAPLE 2: how do we move from one algorithm to another one with Long Acting Antipsychotics (LAIs)

Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long‐acting injection: A case report

Contact Info

Product

Resources

About